SurgePays (SURG) Competitors

$0.57 -0.03 (-4.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.00 (+0.65%)

As of 07:43 PM Eastern

SURG vs. ECOR, SRTS, LUNG, DXR, and COCH

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include electroCore (ECOR), Sensus Healthcare (SRTS), Pulmonx (LUNG), Daxor (DXR), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry.

How does SurgePays compare to electroCore?

electroCore (NASDAQ:ECOR) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

electroCore has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

electroCore has a net margin of -44.08% compared to SurgePays' net margin of -63.32%. SurgePays' return on equity of -967.32% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
SurgePays	-63.32%	-967.32%	-241.91%

electroCore has higher earnings, but lower revenue than SurgePays. electroCore is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.67	-$13.97M	-$1.77	N/A
SurgePays	$56.96M	0.25	-$36.07M	-$1.81	N/A

electroCore currently has a consensus price target of $18.00, suggesting a potential upside of 179.94%. SurgePays has a consensus price target of $5.00, suggesting a potential upside of 773.67%. Given SurgePays' higher probable upside, analysts clearly believe SurgePays is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.7% of electroCore shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 13.8% of electroCore shares are held by company insiders. Comparatively, 29.1% of SurgePays shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, electroCore had 14 more articles in the media than SurgePays. MarketBeat recorded 19 mentions for electroCore and 5 mentions for SurgePays. SurgePays' average media sentiment score of 0.78 beat electroCore's score of 0.44 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
electroCore	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

electroCore beats SurgePays on 8 of the 14 factors compared between the two stocks.

How does SurgePays compare to Sensus Healthcare?

Sensus Healthcare (NASDAQ:SRTS) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Sensus Healthcare has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Sensus Healthcare has a net margin of -34.50% compared to SurgePays' net margin of -63.32%. Sensus Healthcare's return on equity of -15.41% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.41%	-13.70%
SurgePays	-63.32%	-967.32%	-241.91%

Sensus Healthcare has higher earnings, but lower revenue than SurgePays. Sensus Healthcare is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	2.16	-$7.72M	-$0.47	N/A
SurgePays	$56.96M	0.25	-$36.07M	-$1.81	N/A

Sensus Healthcare currently has a consensus price target of $6.88, suggesting a potential upside of 90.44%. SurgePays has a consensus price target of $5.00, suggesting a potential upside of 773.67%. Given SurgePays' higher probable upside, analysts clearly believe SurgePays is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by company insiders. Comparatively, 29.1% of SurgePays shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Sensus Healthcare had 6 more articles in the media than SurgePays. MarketBeat recorded 11 mentions for Sensus Healthcare and 5 mentions for SurgePays. SurgePays' average media sentiment score of 0.78 beat Sensus Healthcare's score of 0.10 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
SurgePays	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sensus Healthcare beats SurgePays on 11 of the 16 factors compared between the two stocks.

How does SurgePays compare to Pulmonx?

SurgePays (NASDAQ:SURG) and Pulmonx (NASDAQ:LUNG) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

SurgePays currently has a consensus price target of $5.00, suggesting a potential upside of 773.67%. Pulmonx has a consensus price target of $5.38, suggesting a potential upside of 301.39%. Given SurgePays' higher possible upside, equities research analysts clearly believe SurgePays is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

SurgePays has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

In the previous week, SurgePays had 4 more articles in the media than Pulmonx. MarketBeat recorded 5 mentions for SurgePays and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat SurgePays' score of 0.78 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Pulmonx	Very Positive

6.9% of SurgePays shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 6.8% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pulmonx has a net margin of -60.09% compared to SurgePays' net margin of -63.32%. Pulmonx's return on equity of -92.94% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-63.32%	-967.32%	-241.91%
Pulmonx	-60.09%	-92.94%	-39.80%

SurgePays has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.25	-$36.07M	-$1.81	N/A
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A

Summary

Pulmonx beats SurgePays on 10 of the 16 factors compared between the two stocks.

How does SurgePays compare to Daxor?

SurgePays (NASDAQ:SURG) and Daxor (NASDAQ:DXR) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

SurgePays currently has a consensus price target of $5.00, suggesting a potential upside of 773.67%. Given SurgePays' higher possible upside, equities research analysts clearly believe SurgePays is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

SurgePays has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Daxor has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

In the previous week, SurgePays had 4 more articles in the media than Daxor. MarketBeat recorded 5 mentions for SurgePays and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat SurgePays' score of 0.78 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Daxor	Very Positive

6.9% of SurgePays shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 59.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to SurgePays' net margin of -63.32%. Daxor's return on equity of 0.00% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-63.32%	-967.32%	-241.91%
Daxor	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than SurgePays.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.25	-$36.07M	-$1.81	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Daxor beats SurgePays on 6 of the 11 factors compared between the two stocks.

How does SurgePays compare to Envoy Medical?

SurgePays (NASDAQ:SURG) and Envoy Medical (NASDAQ:COCH) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

SurgePays has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

In the previous week, SurgePays had 3 more articles in the media than Envoy Medical. MarketBeat recorded 5 mentions for SurgePays and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 1.63 beat SurgePays' score of 0.78 indicating that Envoy Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Envoy Medical	Very Positive

SurgePays currently has a consensus price target of $5.00, suggesting a potential upside of 773.67%. Envoy Medical has a consensus price target of $6.00, suggesting a potential upside of 803.89%. Given Envoy Medical's stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than SurgePays.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

6.9% of SurgePays shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 7.1% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SurgePays has a net margin of -63.32% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-63.32%	-967.32%	-241.91%
Envoy Medical	-9,875.64%	N/A	-177.92%

Envoy Medical has lower revenue, but higher earnings than SurgePays. Envoy Medical is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.25	-$36.07M	-$1.81	N/A
Envoy Medical	$240K	212.64	-$23.76M	-$1.01	N/A

Summary

Envoy Medical beats SurgePays on 11 of the 16 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$15.03M	$16.43B	$39.25B	$12.38B
Dividend Yield	N/A	4.90%	3.19%	5.35%
P/E Ratio	-0.32	49.52	157.84	23.07
Price / Sales	0.25	43.10	630.21	79.28
Price / Cash	N/A	64.09	49.49	56.33
Price / Book	-0.87	9.14	10.32	6.96
Net Income	-$36.07M	$379.18M	$1.03B	$333.52M
7 Day Performance	2.58%	-3.89%	0.39%	0.45%
1 Month Performance	-30.92%	5.14%	9.60%	4.06%
1 Year Performance	-77.38%	-8.03%	164.81%	36.24%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	2.9225 of 5 stars	$0.57 -4.3%	$5.00 +773.7%	-82.2%	$15.03M	$56.96M	N/A	40	Upcoming Earnings
ECOR electroCore	2.5666 of 5 stars	$6.79 +2.7%	$18.00 +165.1%	+33.9%	$55.94M	$32.03M	N/A	50	Analyst Revision
SRTS Sensus Healthcare	3.8055 of 5 stars	$3.39 -0.7%	$6.88 +103.1%	-24.8%	$55.72M	$27.48M	N/A	40	Earnings Report
LUNG Pulmonx	2.6307 of 5 stars	$1.28 -1.9%	$5.38 +321.8%	-59.9%	$53.86M	$90.50M	N/A	250	Positive News
DXR Daxor	2.6134 of 5 stars	$10.45 +4.0%	N/A	+43.0%	$52.65M	$10.30M	N/A	37	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors

SURG vs. ECOR, SRTS, LUNG, DXR, and COCH

How does SurgePays compare to electroCore?

Summary

How does SurgePays compare to Sensus Healthcare?

Summary

How does SurgePays compare to Pulmonx?

Summary

How does SurgePays compare to Daxor?

Summary

How does SurgePays compare to Envoy Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SurgePays (SURG) Competitors

SURG vs. ECOR, SRTS, LUNG, DXR, and COCH

How does SurgePays compare to electroCore?

Which has more volatility and risk, ECOR or SURG?

Is ECOR or SURG more profitable?

Which has stronger earnings and valuation, ECOR or SURG?

Do analysts rate ECOR or SURG?

Do insiders & institutionals believe in ECOR or SURG?

Does the media refer more to ECOR or SURG?

Summary

How does SurgePays compare to Sensus Healthcare?

Which has more volatility and risk, SRTS or SURG?

Is SRTS or SURG more profitable?

Which has stronger earnings and valuation, SRTS or SURG?

Do analysts rate SRTS or SURG?

Do insiders & institutionals believe in SRTS or SURG?

Does the media refer more to SRTS or SURG?

Summary

How does SurgePays compare to Pulmonx?

Do analysts rate SURG or LUNG?

Which has more risk and volatility, SURG or LUNG?

Does the media refer more to SURG or LUNG?

Do insiders & institutionals believe in SURG or LUNG?

Is SURG or LUNG more profitable?

Which has higher earnings & valuation, SURG or LUNG?

Summary

How does SurgePays compare to Daxor?

Do analysts rate SURG or DXR?

Which has more risk and volatility, SURG or DXR?

Does the media refer more to SURG or DXR?

Do insiders & institutionals believe in SURG or DXR?

Is SURG or DXR more profitable?

Which has higher earnings & valuation, SURG or DXR?

Summary

How does SurgePays compare to Envoy Medical?

Which has more risk and volatility, SURG or COCH?

Does the media refer more to SURG or COCH?

Do analysts rate SURG or COCH?

Do insiders & institutionals believe in SURG or COCH?

Is SURG or COCH more profitable?

Which has higher earnings & valuation, SURG or COCH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools